Drug legislation and regulation as part of the health care system Valerio Reggi, Eshetu Wondemagegnehu HTP/EDM/QSM - 3 October 2001 1 PAR Seminar, 3

Download Report

Transcript Drug legislation and regulation as part of the health care system Valerio Reggi, Eshetu Wondemagegnehu HTP/EDM/QSM - 3 October 2001 1 PAR Seminar, 3

Drug legislation and regulation as
part of the health care system
Valerio Reggi, Eshetu Wondemagegnehu
HTP/EDM/QSM - 3 October 2001
1 PAR Seminar, 3 October 2002
WHO - EDM
Outline of presentation
• Rationale for state role
• Key elements of legislation
• Key elements of regulatory
system
• Regulation and public health
2 PAR Seminar, 3 October 2002
WHO - EDM
Drug legislation and regulation
Rationale for state
role
Key elements of drug
legislation
Key elements of drug
regulatory system
Drug regulation and
public health
3 PAR Seminar, 3 October 2002
WHO - EDM
Rationale for state role
Regulation in medicine is 4000 years old
Hammurabi's Code of Laws (~ 2000 BCE):

physician fees adapted to patient’s status:
215. …a physician …… shall receive ten shekels in
money.
216. If the patient be a freed man, he receives five
shekels.
217. If the patient be the slave …… two shekels.

sanctions for malpractice:
218. If a physician make a large incision with the operating knife and kill
the patient or …. … cut out the eye, his hands shall be cut off.
4 PAR Seminar, 3 October 2002
WHO - EDM
Rationale for state role
Essential state functions in the pharmaceutical
sector
Essential means that if the public
sector is unable to perform these
functions, public health goals
cannot be achieved and the least
privileged part of the population
will suffer.
5 PAR Seminar, 3 October 2002
WHO - EDM
Rationale for state role
Essential state functions in the
pharmaceutical sector

Policy making, priority setting:

Regulation & control:

Professional standards:
what are
the problems? how do we address them? how do
we know what we have achieved?
what are the rules?
are the rules respected? do we need to change
rules?
who is allowed to
do what?

Access to drugs: can people use the drugs
they need?

Information: can people use drugs properly?
6 PAR Seminar, 3 October 2002
WHO - EDM
Market failure:


Equity: who cares for the poor? Public/private mix
Information imbalance: access to and capacity to
assess and compare information on quality, safety,
efficacy, value for money, appropriateness

External benefits:

Failure of competition:

Market asymmetry:
immunizations and treatment of
contagious diseases benefit all, if left to market laws
alone many will not be immunized or treated
who can develop new
drugs? who can influence prescription/consumption?
who takes the less profitable activities? competition
based on product differentiation rather than price
who pays does not choose,
who chooses does not pay
7 PAR Seminar, 3 October 2002
WHO - EDM
Dr. Gro Harlem Brundtland
Director General
8 PAR Seminar, 3 October 2002
“…. drugs are a
public good and not
simply just another
commodity: first for
their high social
value, and then
because consumers
and prescribers are
unable to assess
their quality, safety
and efficacy.”
WHO - EDM
Rationale for state role
Selection of essential drugs is a two-step process:
1 - market approval of a pharmaceutical product
on the basis of efficacy, safety and quality. This
regulatory decision defines the availability of the
drug in the market.
2 - most public drug procurement schemes have
mechanisms to limit procurement or
reimbursements to certain drugs. For these
decisions an evaluation is necessary, based on a
comparison between various drug products and on
considerations of “value for money”.
9 PAR Seminar, 3 October 2002
WHO - EDM
Rationale for state role
The reality (or the paradox) :
- only richer countries make use of this second
selection step, and therefore enact mechaisms to
rationalise consumption and keep expenditure
under control,
- in poorer countries, where health insurance
mechanisms are not fully developed and people
pay most drug out of pockets, there ar no
adequate mechanisms to protect consumers
10 PAR Seminar, 3 October 2002
WHO - EDM
Rationale for state role
In industrialized countries regulatory work
takes place in an environment characterized by
longer-established regulatory traditions. In
addition, there is a relatively mature
interaction of interests, actions, and views of
regulators, industry with different focuses
(innovative medicines, generics, OTC products,
‘alternative’ medicines), professionals, patient
and consumers groups, and individuals.
11 PAR Seminar, 3 October 2002
WHO - EDM
Rationale for state role
In developing countries regulation is often
less consolidated than in industrialized
countries, and the interaction between the
different interested parties is not always
balanced. In addition, the resources that can
be made available for the implementation of
regulatory work and control are not always
adequate for the task that regulatory
authorities are expected to undertake. This
puts special responsibility and burden on
decision makers and regulatory officials of
developing countries.
12 PAR Seminar, 3 October 2002
WHO - EDM
Rationale for state role
Consequences of weak drug regulatory capacity
Irrational consumption and prescription,
substandard, counterfeit, harmful,
useless drugs on sale
13 PAR Seminar, 3 October 2002
WHO - EDM
Drug legislation and regulation
Rationale for state
role
Key elements of drug
legislation
Key elements of drug
regulatory system
Drug regulation and
public health
14 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Purposes of drug legislation




Distinguish “permissible” or “lawful” from
“impermissible” or “unlawful”
Specify rights, duties, powers
Provide a legal basis for regulation
Specify sanctions and penalties to be
imposed upon those who violate
legislation or regulations.
15 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Scope of drug legislation






What products should be regulated
What companies/institutions should be regulated
What activities should be regulated
To what extent should the above be regulated
Who should be responsible for regulation
What sanctions should apply in case of violations
16 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Items of drug legislation (1)
 Technical aspects (title, date of operation, areas of
application/exclusion, relationship to other existing
laws, transitional arrangements).
 Definitions of terms and concepts
 Statutory powers (right of inspection), duties and
responsibilities of the regulatory authority, and its
organization and resources
 Requirement for company and product licensing
and duration of validity of licences
17 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Items of drug legislation (2)
 Special issues: e.g. patents, prices, clinical trials,
post-marketing surveillance, conflicts of interest,
access to information, advertising and promotion
 Enforcement procedures, penal provisions, and
administrative penalties
 Right of complaint and appeal against regulatory
decisions
 Scope and power of regulation-making (i.e. main
text must authorize that additional provisions are
made through regulations)
18 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Definitions in drug legislation (1)
Products subject to legislation:
•
clear, unambiguous, comprehensive definition of
medicinal product:
Any substance or pharmaceutical product for
human or veterinary use that is intended to
modify or explore physiological systems or
pathological states for the benefit of the recipient.
19 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Definitions in drug legislation (2)
“Borderline” products: criteria and attitudes change,
new problems arise
•
•
flexibility to enable DRA to cover specific classes of
product to be within scope of law
public
health approach
demands
claims
in promotion/labelling
and
consumer that
perception
decide
a productperceive
is for medicinal
(tonics, be
food
whatif people
as a purpose
drug should
supplements,
soaps and shampoos)
regulated vitamins,
as a drug
20 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Definitions in drug legislation (3)
The term "medicinal product" must include, at least:
pharmaceutical, biological (vaccines, blood products,
other biologicals) and herbal products, including
traditional medicines (not harvested by traditional
medicine practitioners and sold in package form),
products known in many countries as "pharmafoods",
"nutriceuticals", or "cosmeceuticals" intended for
therapeutic use and whether for animal or human use.
WHO Expert Committee on Specifications for Pharmaceutical
Preparations. 1998, WHO Technical Report Series, No.885
21 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Definitions in drug legislation (4)
The drug regulatory authority must also determine to
what extent it intends to exempt related products, such
as diagnostic materials, medical devices, cosmetics,
health foods and food supplements from its scope of
issuing marketing authorizations. ……... In borderline
cases it might be left to the regulatory authority to
decide whether a substance or preparation is considered
as a medicinal product.
WHO Expert Committee on Specifications for Pharmaceutical
Preparations. 1998, WHO Technical Report Series, No.885
22 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Definitions in drug legislation (5)
Activities subject to legislation:
The legislation must apply to all institutions and
individuals, within both the public and private
sectors, that are engaged in, or connected with
any aspect of manufacture, promotion,
procurement, distribution, sale or supply of
medicinal products.
WHO Expert Committee on Specifications for Pharmaceutical
Preparations. 1998, WHO Technical Report Series, No.885
23 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Definitions in drug legislation (6)
Statutory powers in legislation:
primary responsibility of the national drug
regulatory authority is to operate a system
of administration and enforcement
intended to achieve the objectives of the
legislation
WHO Expert Committee on Specifications for Pharmaceutical
Preparations. 1998, WHO Technical Report Series, No.885
24 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug legislation
Definitions in drug legislation (7)
Statutory powers in legislation:
A department of veterinary services or a department
dealing with traditional medicine practices may exert
administrative oversight of services without
exercising regulatory control over the
products used within the specific discipline.
……… ensure close and effective coordination
between all concerned parties.
WHO Expert Committee on Specifications for Pharmaceutical
Preparations. 1998, WHO Technical Report Series, No.885
25 PAR Seminar, 3 October 2002
WHO - EDM
Drug legislation and regulation
Rationale for state
role
Key elements of drug
legislation
Key elements of drug
regulatory system
Drug regulation and
public health
26 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug regulatory system
Drug regulation comprises all the legal, administrative
& technical arrangements meant to ensure that:





all premises, persons & practices engaged in the
development, manufacture, importation,
exportation, wholesale, supply, dispensing &
promotion of drugs comply with approved
standards, norms, procedures and requirements
drug products are safe, effective and of acceptable
quality
product information is unbiased, accurate and
appropriate
drugs are available
drugs are used rationally
27 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug regulatory system
Basic functions in drug regulation (1)




Licensing of manufacturers, importers,
distributors, wholesale and retail outlets
(premises, persons and practices)
Marketing authorization for drug products
Quality control laboratory testing
Provision of drug information and
monitoring of drug promotion and
advertising
Continues……...
28 PAR Seminar, 3 October 2002
WHO - EDM
Key elements of drug regulatory system
….continued






Basic functions in drug regulation (2)
Inspection of manufacturing and
distribution channel premises
Adverse drug reaction monitoring
Authorization of clinical trials
Monitoring of drug dispensing and
prescribing practices
Monitoring of drug utilization and
promotion of rational drug use
Application of sanctions
29 PAR Seminar, 3 October 2002
WHO - EDM
Drug regulation is a multi- faceted activity at
the centre of complex interactions
Government
Manufacturers
Products
Regulatory
authority
Experts
Prescribers
Medicines
Importers/Wholesalers/Retailers
30 PAR Seminar, 3 October 2002
Patients/Consumers
WHO - EDM
Drug regulation is a multi- faceted activity at
the centre of complex interactions
Government
Manufacturers
Products
Regulatory
authority
Experts
Prescribers
Medicines
Importers/Wholesalers/Retailers
31 PAR Seminar, 3 October 2002
Patients/Consumers
WHO - EDM
Drug regulation is a multi- faceted activity at
the centre of complex interactions
Government
Manufacturers
Products
Regulatory
authority
Experts
Prescribers
Medicines
Importers/Wholesalers/Retailers
32 PAR Seminar, 3 October 2002
Patients/Consumers
WHO - EDM
Drug regulation is a multi- faceted activity at
the centre of complex interactions
Government
Manufacturers
Products
Regulatory
authority
Experts
Prescribers
Medicines
Importers/Wholesalers/Retailers
33 PAR Seminar, 3 October 2002
Patients/Consumers
WHO - EDM
Drug regulation is a multi- faceted activity at
the centre of complex interactions
Government
Manufacturers
Products
Regulatory
authority
Experts
Prescribers
Medicines
Importers/Wholesalers/Retailers
34 PAR Seminar, 3 October 2002
Patients/Consumers
WHO - EDM
The challenges:

the health system counts on DRA for good, safe,
and effective medicines and for fair rules and
control on drug trade, information, and use

any strategy to improve anything in the
pharmaceutcal area involves DRA

any problem encountered in the pharmaceutical
area has something to do with the DRA
35 PAR Seminar, 3 October 2002
WHO - EDM
Country strategies for achieving effective
drug regulation
1.
Assess drug regulation performance
2.
Identify and develop priority functions
3.
Provide clear mission and purpose
4.
Create a supportive environment
5.
Formulate adequate legislation
6.
Create appropriate organisational structure
7.
Allocate adequate human and financial resources
8.
Minimise corruption and conflict of interest
9.
Apply appropriate regulatory & enforcement
strategies
36 PAR Seminar, 3 October 2002
WHO - EDM
Effective regulation depends on the
environment







adequate consideration is given to the public health
value of drugs
drug regulation is not fragmented
DRA is also accountable to the public
drug regulation processes are transparent
appropriate sanctions are regularly applied
strong, organised public interest groups are incentived
to support drug regulatory activities
there is freedom of association and information
37 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
• Political will and commitment:
 clear, firm, and equitable legislation addressing
all the relevant issues and carries appropriate
sanctions;
 financial and other resources that are
commensurate with the designated functions;
 willingness to defend decisions and policies
which are to the benefit of public health;
 support when legislated sanctions are imposed
for violations of legislation.
38 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
• Accountability :
 means being required to account for one’s
conduct and actions, usually to an individual or
group but ultimately to the public;
 field of medicines is highly commercialized, it is
characterized by extreme pressures on the DRA
and by intensive lobbying from stakeholders at
many levels;
 a system of accountability is essential in
managing these tensions.
39 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
•
Mechanisms to ensure accountability:




requirement to provide public reports;
publication of decisions, processes and policies;
mechanism for appeals against DRA decisions;
code of conduct for DRA staff and procedure for
complaints about actions of DRA and conduct of
individual staff;
 formalized mechanisms for consulting experts;
 web site with information about the DRA
40 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
•
Staff skills:
 evaluators should be qualified in pharmacy, clinical
pharmacology, medicine or a similar discipline;
 external expertise should also be available, but
authority’s own staff must be capable of
understanding and implementing expert advisory
body’s recommendations;
 DRA needs staff to investigate breaches of
legislation and initiate action in the courts;
 a suitable number of competent administrative staff
and computer specialists.
41 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
•
Staff number:
Number of staff depends on responsibilities to be
undertaken.
Major determinants of staff numbers:
 degree to which DRA is prepared to rely on
decisions made, and reports prepared, by DRA in
other countries;
 presence of local pharmaceutical industry;
 number of products to be processed.
42 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
•
Staff training:
 Routine training for new staff;
 Scientific skills must be continuously updated
to keep pace with drug discovery and
development;
 It is therefore essential for suitable training and
practical experience to be offered regularly to
the staff concerned.
43 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
• Premises:
 Data submitted by applicants should be stored
with sufficient security to give the applicants
the confidence that they cannot be subject to
theft or unauthorized copying.
 Professional staff whose responsibilities
include sustained periods of concentration will
perform more efficiently (in terms of output and
reliability) in quiet surroundings.
44 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Computerized system:
• progress of assessment of applications;
• premises for which an inspection is due;
• date of latest approved product information;
• previous decisions taken on same or similar active
ingredient & guidance for assessment;
• list of marketing authorizations due to expire;
• regular reports and lists;
• automation of administrative tasks;
• alerts for deadlines.
45 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Access to the Internet:
• information from web sites of other DRAs;
• access to technical literature;
• up-to-date safety information;
• access to web sites of professional associations
and NGOs.
Own web site:
• information on decisions;
• regulatory information;
• safety information and alerts;
• open channel for receiving input from society.
46 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Expert advice:
• local expertise from universities, research institutes, and
health care facilities (all levels);
• individuals whose advice is seen by community, health
workers and government as authoritative and credible;
• fixed-term assignments to reduce risk of dependence on
political considerations;
• set broad technical policies so that only difficult applications
need to be referred;
• declaration of “no conflict of interest” before and during
activities of the expert advisory body;
• reimbursement travel and accommodation plus reasonable
remuneration not related to outcome of evaluation.
47 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Fees and cost recovery:
• for all applications and unrelated to outcome;
• certifications & annual fees (support PM activities);
• high enough to contribute significantly to effective
functioning of DRA without affecting drug price;
• conducting services for profit is contrary to purpose
and ethic of and distracts from regulatory work;
• fees relate to amount of work (fees for generics are
lower because they require less assessment work);
• low or no fees for vital drugs with limited market,
annual fee can be based on annual sales;
• fee structure should be transparent.
48 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Special access schemes:
• allow access to unregistered drug products in
special or emergency situations;
• avoid de facto marketing.
49 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Transparency (1):
DRA must answer to both government and the
public on:
how it fulfils its mission to protect public
health;
how it prevents corruption;
how it prevents decisions unfair to those
regulated.
50 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Transparency (2):
• printed and published policies and procedures;
• give reasons for decisions;
• transparency is the most efficient way to work:
- no time spent clarifying policies and attitudes;
- terminology is defined so that the parties use
the same terms to mean the same thing;
- risk of arbitrary decisions is reduced;
- DRA’s image is ‘they implement rules’ rather
than ‘they decide’;
- ‘competence’ vs ‘bureaucracy’.
51 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Written policies:
• decisions on individual applications become easier;
• examples:
when data on bioequivalence are required;
when evaluation reports prepared by another
DRA will be accepted;
which fixed-dose combinations are considered
rational;
when and from which countries certificates are
accepted;
what are the acceptable reference sources for
drug information.
-
52 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Written procedures:
•
•
•
•
staff understand their own role;
assessment deadlines are predictable;
lines of communication are clear;
documentation and reasons for decisions
accessible and are easy to identify;
• SOP: written procedure giving instructions for
performing operations (e.g., reception of
applications, individual steps of assessment,
issuance of marketing authorization, equipment
operation, validation of analytical methods)
53 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Example of part of SOP on WHO-type certificate:
Decision tree for WHO-type certificate
Obtain WHO-type
Certificate
Issueing authority is in list of reference countries?
Yes
No
Does product have MA in exporting country?
Yes
No
Check if product is exactly the same
Review product information and adapt if necessary
Review bioequivalence if required
Review stability data if required
Check if analytical methods are applicable in QC lab
54 PAR Seminar, 3 October 2002
Proceed as if no
certificate was
submitted
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Quality system:
• infrastructure, encompassing organizational
structure, procedures, processes, and resources;
• organized set of actions necessary to ensure that
patients, applicants, and regulators are satisfied
that assessment and decisions are within legal
requirements and guidance, and consistent with
protection and promotion of public health.
55 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Quality manual:
• contains defined and documented DRA’s policies
and objectives;
• DRA must ensure that policies are understood
and implemented at all levels in the DRA;
• describe legal status of all elements of DRA (drug
registration, inspectorate, QC lab, etc.);
• code of ethics and conduct relating to all DRA
activities;
• names, qualifications, and terms of reference of
the senior staff and other DRA personnel, both
internal and external;
……………
56 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Quality manual (continued):
• training strategies and arrangements for all DRA
staff;
• organization chart showing lines of authority,
responsibility and allocation of functions;
• documented procedures for issue, suspension
and revocation of marketing authorizations;
• list of subcontractors used for specific DRA work
and details of the documented procedures for
assessing and monitoring their competence;
• details of appeals procedures;
………….
57 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
Quality manual (continued):
• procedure for ensuring that complaints are
investigated and shortcomings revealed;
• list of staff members responsible for investigating
complaints and those with authority to take
remedial action;
• system of records which demonstrates
compliance with obligations under national
legislation and demonstrates that the quality
system is operating satisfactorily.
58 PAR Seminar, 3 October 2002
WHO - EDM
The EMEA Quality Manual/Documentation System Structure
EMEA Mission Statement &
Quality Policy
EMEA Policies
EMEA Core & Key Tasks
(Process
Maps/Flowcharts)
EMEA SOPs
EMEA Forms
Standard Documents
Templates
59 PAR Seminar, 3 October 2002
WHO - EDM
The EMEA Quality Manual/Documentation System Structure
EMEA Forms
Standard Documents
Templates
EMEA SOPs
EMEA Core & Key Tasks
(Process
Maps/Flowcharts)
EMEA Policies
EMEA Mission Statement &
Quality Policy
60 PAR Seminar, 3 October 2002
WHO - EDM
PROVISIONS AND PREREQUISITES FOR
REGULATORY CONTROL
• A regulatory “culture” :
 DRA should lead its staff to independent
thinking, impartiality and pride in their work.
 Everyone should be motivated by a desire to
ensure that effective, safe and good-quality
drug products are available to the public in
adequate quantities and are used rationally.
 It should be stressed that staff who succumb to
favours from outside sources are damaging the
reputation of the whole organization, including
that of their colleagues.
61 PAR Seminar, 3 October 2002
WHO - EDM
Drug legislation and regulation
Rationale for state
role
Key elements of drug
legislation
Key elements of drug
regulatory system
Drug regulation and
public health
62 PAR Seminar, 3 October 2002
WHO - EDM
World Health Assembly resolution 52.19
24 May 1999: WHO’s Revised Drug
Strategy
URGES Member States:
(1) to reaffirm their commitment to …… taking all
necessary concrete measures in order to ensure
equitable access to essential drugs;
(2) to ensure that public health interests are
paramount in pharmaceutical and health policies;
(3) to explore and review their options under
relevant international agreements, including trade
agreements, to safeguard access to essential
drugs;
63 PAR Seminar, 3 October 2002
WHO - EDM
World Health Assembly resolution 52.19 24
May 1999: WHO’s Revised Drug Strategy
Implications for drug regulatory authorities:
- put public health as first priority of regulatory
system development strategy and decisions
- contribute to develop market of good quality, safe,
effective,and affordable drugs
- improve drug assessment and market control
Improve regulatory system's capacity to meet
needs of health professionals and public
64 PAR Seminar, 3 October 2002
WHO - EDM
Access to quality drugs:
To ensure access to quality drugs
there is no better strategy than
building a reliable and effective
national drug regulatory authority
65 PAR Seminar, 3 October 2002
WHO - EDM
Drug regulation and public health
Good regulatory practice requires:





Mission and objectives clearly stated
Possibility to assess attainment of objectives
Procedures and outcomes transparent to
applicants, health professionals, and public
Arguments used to reach decision accessible
to the public
Reasonable duration of assessment without
compromising quality, safety & efficacy
9th ICDRA 29/4/1999
66 PAR Seminar, 3 October 2002
WHO - EDM
Drug regulation and public health
Good regulatory practice requires:




Expedite review for orphan and
outstanding public-health-value drugs
Accountability to government, those
regulated, and the public
Personnel adequately trained, highly
qualified, of high integrity
Human resource development programme
9th ICDRA 29/4/1999
67 PAR Seminar, 3 October 2002
WHO - EDM
Drug regulation and public health
Good regulatory practice requires:




Mechanisms for appeal and for citizens'
complaints
Access to appropriate knowledge and
technology
Citizens are provided with accurate and
appropriate drug information
Mechanisms to ensure quality of
operating procedures
9th ICDRA 29/4/1999
68 PAR Seminar, 3 October 2002
WHO - EDM
Drug regulation and public health
No national authority meets all criteria,
......but some are closer than others
All want to improve,
.... but some are much better placed
69 PAR Seminar, 3 October 2002
WHO - EDM
Big gaps exist
TECHNICAL COMPLEXITY OF
REQUIREMENTS
ICH
IC
LDC
70 PAR Seminar, 3 October 2002
WHO - EDM
Thousands of highly qualified professionals
Thousands of highly qualified external
experts
Virtually unlimited access to the most
sophisticated technology and knowledge
71 PAR Seminar, 3 October 2002
WHO - EDM
Gaps also exist between nonICH counties: e.g. between
newer and older members of
ASEAN
Harmonisation
Mutual understanding,
...or one-way understanding?
72 PAR Seminar, 3 October 2002
WHO - EDM
No importable models:
..approach to drug regulation must be attuned to
available resources...
...problems in establishing drug control have too
often resulted from the adaptation of provisions
successful elsewhere but of a complexity that
precludes their effective implementation in the
country of adoption...
WHO Expert Committee on Specifications for Pharmaceutical Preparations, TSR 790, 1990
73 PAR Seminar, 3 October 2002
WHO - EDM
Drug regulation and public health
Setting priorities based on available resources:
 ensure effective market control:
 establish list of authorized/marketed products,
 strengthen inspection of distribution channels (if
appropriate limit number of entry points for imported
drugs and number of distributors),
 establish adequate sanctions for violators;
 establish GMP requirement and inspections;
 identify ‘reference’ DRAs for reports, decisions, drug
information, safety alerts;
 focus on regulation and control of generics;
 build collaboration with academic and research intitutions
and NGOs to address drug selection and rational use.
74 PAR Seminar, 3 October 2002
WHO - EDM
Huge differences in regulatory environment
do exist.
What can regulators do?
Wait for political will, improved legislation, more
resources to appear ?

Or rather try to improve regulatory work with current
environment and resources in order to maximise its
potential for improving public health?

75 PAR Seminar, 3 October 2002
WHO - EDM